Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflammatory demyelinating polyneuropathy: an exploratory real-world multicenter cohort study
Study Overview The study investigates the efficacy of three therapeutic agents—ripertamab, rituximab, and efgartigimod—in treating chronic inflammatory demyelinating polyneuropathy (CIDP), […]
